| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 17.89 | 1.6% |
| Total Income | 17.93 | 3.7% |
| Expenditure | 15.63 | 2.1% |
| PBT | 2.30 | 13.3% |
| Net Profit | 1.73 | 20.8% |
| OPM | 14.80% | 0.44pp |
| NPM | 9.65% | 2.10pp |
| EPS | 1.46 | 20.6% |
Sanjivani Paranteral Ltd Reports 8.9% YoY Revenue Growth in Q1 FY26, Despite Injectables Segment Surge and Oral Segment Decline
12 Aug 2025 · 12 Aug 2025, 04:52 pm
Summary
Sanjivani Paranteral Ltd, a pharmaceutical company specializing in parenteral and oral solid products, reported a steady performance for Q1 FY26. Despite challenges in the global trade environment and a decline in the oral segment, the company achieved an 8.9% YoY revenue growth, with the injectables segment reporting a 47.1% YoY increase. Exports, which contributed significantly to the overall revenue, accounted for 73.7% of the total revenue. The company remains committed to its long-term strategy, investing in R&D to expand its product portfolio.
Key Highlights
- 1
Revenue from operations grew 8.9% YoY to Rs. 178.9 mn.
- 2
EBITDA margin stood at 15.0% (up 26 bps YoY).
- 3
Profit After Tax (PAT) stood at Rs. 17.3 mn. (up 1.0% YoY).
- 4
Injectables segment revenue grew by 47.1% YoY to Rs. 89.9 mn.
- 5
Oral segment revenue declined by 11.1% YoY to Rs. 88.2 mn.
- 6
Exports constitute 73.7% of total revenue, while domestic constitutes the rest.
- 7
Core markets of CIS (incl Russia), the Middle East & Africa and Latin America, accounted for 73.7% to Rs. 131.9 mn.
Management Comments
Mr. Ashwani Khemka
We are pleased to report a steady performance for Q1FY26, in the backdrop of challenges and uncertainties in the global trade environment. While the injectables segment reported strong growth, oral segment was impacted by shipment related challenges due to macro uncertainties. This will improve as we look into the coming quarters. Our commitment to long-term strategy remains unwavering. We are actively investing in R&D to expand our product portfolio. The continued performance of our export markets, which contributed significantly to our overall revenue, is a testament to this strategy. Despite the challenges posed by a dynamic global environment, our diversified portfolio and strategic focus should help us achieve significant revenue growth going ahead.
Informational and educational content only. Not investment advice.